ArticleThe Journal of investigative dermatology2012
Histology-specific microRNA alterations in melanoma.
Article in The Journal of investigative dermatology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 50 citations in OpenAlex.
- MRGBMDAT: a multi-relational graph encoder network with bilinear fusion for miRNA-disease association type prediction.Bioinformatics (Oxford, England) · 2026Article
- Multiple roles of MicroRNAs in melanoma: biomarkers for diagnosis, prognosis, and treatment prediction.Frontiers in immunology · 2026Review
- Tumor miRNA Signatures Associate with Outcomes of Patients with Stage II/III Melanoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- miR-933 accelerates the growth of liver cancer cells by enhancing pyruvate kinase isoform M2.Genes & diseases · 2024Article
- Associations between TERT Promoter Mutations and Survival in Superficial Spreading and Nodular Melanomas in a Large Prospective Patient Cohort.The Journal of investigative dermatology · 2022Article
- Human mesenchymal stem cell derived exosomes inhibit the survival of human melanoma cells through modulating miR-138-5p/SOX4 pathway.Cancer biomarkers : section A of Disease markers · 2022Article
- miR-138-5p induces aggressive traits by targeting Trp53 expression in murine melanoma cells, and correlates with poor prognosis of melanoma patients.Neoplasia (New York, N.Y.) · 2021Article
- CircMEG3 inhibits telomerase activity by reducing Cbf5 in human liver cancer stem cells.Molecular therapy. Nucleic acids · 2021Article
- miR-155 overexpression is followed by downregulation of its target gene, NFE2L2, and altered pattern of VEGFA expression in the liver of melanoma B16-bearing mice at the premetastatic stage.International journal of experimental pathology · 2019Article
- Primary Melanoma Histologic Subtype: Impact on Survival and Response to Therapy.Journal of the National Cancer Institute · 2019Article
- Comparison of Circulating miRNAs Expression Alterations in Matched Tissue and Plasma Samples During Colorectal Cancer Progression.Pathology oncology research : POR · 2019Article
- MicroRNA-Directed Cancer Therapies: Implications in Melanoma Intervention.The Journal of pharmacology and experimental therapeutics · 2018Review
- Piceatannol induced apoptosis through up-regulation of microRNA-181a in melanoma cells.Biological research · 2017Article
- Plasma exosome miR-196a and miR-1246 are potential indicators of localized pancreatic cancer.Oncotarget · 2017Article
- Identification of microRNAs associated with invasive and aggressive phenotype in cutaneous melanoma by next-generation sequencing.Laboratory investigation; a journal of technical methods and pathology · 2017Article
- MicroRNAs in melanoma development and resistance to target therapy.Oncotarget · 2017Review
- MicroRNA-15a inhibits the growth and invasiveness of malignant melanoma and directly targets on CDCA4 gene.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- MicroRNA-138 suppresses proliferation, invasion and glycolysis in malignant melanoma cells by targeting HIF-1α.Experimental and therapeutic medicine · 2016Article
- MicroRNA-9 suppresses the growth, migration, and invasion of malignant melanoma cells via targeting NRP1.OncoTargets and therapy · 2016Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
Abstract
We examined the microRNA signature that distinguishes the most common melanoma histological subtypes, superficial spreading melanoma (SSM) and nodular melanoma (NM). We also investigated the mechanisms underlying the differential expression of histology-specific microRNAs. MicroRNA array performed on a training cohort of 82 primary melanoma tumors (26 SSM, 56 NM), and nine congenital nevi (CN) revealed 134 microRNAs differentially expressed between SSM and NM (P<0.05). Out of 134 microRNAs, 126 remained significant after controlling for thickness and 31 were expressed at a lower level in SSM compared with both NM and CN. For seven microRNAs (let-7g, miR-15a, miR-16, miR-138, miR-181a, miR-191, and miR-933), the downregulation was associated with selective genomic loss in SSM cell lines and primary tumors, but not in NM cell lines and primary tumors. The lower expression level of six out of seven microRNAs in SSM compared with NM was confirmed by real-time PCR on a subset of cases in the training cohort and validated in an independent cohort of 97 melanoma cases (38 SSM, 59 NM). Our data support a molecular classification in which SSM and NM are two molecularly distinct phenotypes. Therapeutic strategies that take into account subtype-specific alterations might improve the outcome of melanoma patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.